Date: 29.05.2023

To
The Manager
Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai – 400001

Dear Sir/Madam,

BSE Scrip: PHARMAID | Code: 524572 ISIN: INE117D01018|

Sub: Disclosure of Related Party Transaction for the year ended March 31st 2023

Ref: Compliance under Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith disclosure on Related Party Transaction of the Company for the Financial year ended March 31, 2023.

Submitted for your kind information and record.

Thanking you,

Yours faithfully,

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar (Company Secretary & Compliance Officer)



Pharmaids Pharmaceuticals Limited- Disclosure of Related Party Transactions for the half year /six months ended March 31, 2023

		1		Type of														
S.	Details of the	Details of the coun	etails of the counterparty		ails of the counterparty T		Value of the	Value of	In case r	nonies are	Additional disclosure of related party transactions - applicable only in case the related party							
No	party (listed			related party	related	transaction	due to		transaction	ransaction relates to loans, inter-corporate deposits,								
	entity			transaction	party	during the	either pa	rty as a	advances o	or investm	ents made o	r given by the li	sted entity/s	ubsidiary. T	hese details no	eed to be		
	/subsidiary)			(See Note 5)	transaction	reporting period	result of th	ie	disclosed only once, during the reporting period when such transaction was undertaken.									
	entering into				as	(See Note	transaction											
	the transaction				approved by	6b)			In case	•	financial	Details of the loans, inter-corporate deposits, advances or						
					the				indebtedne	ess is in	curred to	investments						
					audit				make or gi	ve								
					committee				loans, inte	r-corporat	e deposits,							
					(See Note				advances or investments									
	Name	Name	Relationship		6a)		Opening	Closing	Nature	Cost	Tenure	Nature (loan/	Interest	Tenure	Secured/	Purpos		
			of the		,		balance	balance	of	(See		advance/	Rate (%)		unsecured	e for		
			counterparty						indebted	Note		intercorpora				which		
			with the						ness	7)		te deposit/				the		
			listed entity						(loan/			investment				funds		
			or its						issuance							will be		
			subsidiary						of debt/							utilised		
			•						any							by the		
									other							ultimat		
									etc.)							e		
																recipie		
																nt		
																of		
																funds		
																(end-		
																usage)		



		T	1			1										
1.	Pharmaids	Venu Madhava	Key	Remuneration	-	18,00,000.00/-	-	-	-	-	-	-	-	-	-	-
	Pharmaceuticals	Kaparthy –	Management													
	Limited	Executive	Personnel													
		Director														
2.	Pharmaids	Mini	Key	Remuneration	-	12,00,000.00/-	-	-	-	-	-	-	-	-	-	-
	Pharmaceuticals	Manikantan –	Management													
	Limited	Executive	Personnel													
		Director														
3.	Pharmaids	Balagangadhara	Key	Remuneration	-	12,62,903.00/-	-	-	-	-	-	-	-	-	-	-
	Pharmaceuticals	Bidanagere	Management													
	Limited	Channathimmai	Personnel													
		ah - Chief														
		Financial														
		Officer														
4.	Pharmaids	Kaushik Kumar	Key	Remuneration	-	5,61,290.00/-	-	-	-	-	-	-	-	-	-	-
	Pharmaceuticals	- Company	Management													
	Limited	Secretary,	Personnel													
		Compliance														
		Officer & Head-														
		Legal														
5.	Pharmaids	Anugraha	Associate (as	Amount was	-	43,00,000.00/-	_	-	-	-	-	-	-	-	-	-
	Pharmaceuticals	Chemicals	per IND AS)	disbursed as												
	Limited			per the terms												
				of Investment												
				Agreement												
6.	Pharmaids	Chilam Srikanth	Key	Remuneration		3,871.00/-	_	-	-	-		-	-	_		-
J.	Pharmaceuticals	- Chief	Management	Temaneranon		2,071.00/										
	Limited	Financial	Personnel													
	Lillited	Officer	1 CISUIIICI													
		(Resigned on														



		13 th October,														
		2022)														
7.	Pharmaids	Annie Jodhani,	Key	Remuneration		38,223.00/-	-	-	-	-	-	-	-	-	-	-
	Pharmaceuticals	Company	Management													
	Limited	Secretary	Personnel													
		(Resigned on														
		13 th October,														
		2022)														

Notes:

- 1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
- 2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
- 3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
- 4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six-month period shall apply accordingly.
- 5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
- 6. In case of a multi-year related party transaction:
 - a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".



- b. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
- 7. "Cost" refers to the cost of borrowed funds for the listed entity.
- 8. PAN will not be displayed on the website of the Stock Exchange(s).
- 9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar

(Company Secretary, Compliance Officer & Head-Legal)